Overview of Metformin and Neurodegeneration: A Comprehensive Review
Pharmaceuticals · 28.03.2025 · 18 (4) · 486
DOI: 10.3390/ph18040486 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.03.2025. Verfasst von Weronika Kruczkowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Genomics, Faculty of Medicine, Medical University of Lodz, Żeligowskiego 7/9, 90-752 Lodz, Poland. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 332 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, Polish Society of Metabolic Disorders.
Abstract (Originalsprache)
This comprehensive review examines the therapeutic potential of metformin, a well-established diabetes medication, in treating neurodegenerative disorders. Originally used as a first-line treatment for type 2 diabetes, recent studies have begun investigating metformin’s effects beyond metabolic disorders, particularly its neuroprotective capabilities against conditions like Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and multiple sclerosis. Key findings demonstrate that metformin’s neuroprotective effects operate through multiple pathways: AMPK activation enhancing cellular energy metabolism and autophagy; upregulation of antioxidant defenses; suppression of inflammation; inhibition of protein aggregation; and improvement of mitochondrial function. These mechanisms collectively address common pathological features in neurodegeneration and neuroinflammation, including oxidative stress, protein accumulation, and mitochondrial dysfunction. Clinical and preclinical evidence supporting metformin’s association with improved cognitive performance, reduced risk of dementia, and modulation of pathological hallmarks of neurodegenerative diseases is critically evaluated. While metformin shows promise as a therapeutic agent, this review emphasizes the need for further investigation to fully understand its mechanisms and optimal therapeutic applications in neurodegenerative diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Functional Genomics, Faculty of Medicine, Medical University of Lodz, Żeligowskiego 7/9, 90-752 Lodz, Poland.
- Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
- Department of Nucleic Acid Biochemistry, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.
ORCID-Profile: Weronika Kruczkowska, Julia Gałęziewska, Paulina Buczek, Elżbieta Płuciennik, Mateusz Kciuk, Agnieszka Śliwińska
Förderung
- Medical University of Lodz
- Polish Society of Metabolic Disorders
Zitieren
APA
Kruczkowska, W., Gałęziewska, J., Buczek, P., Płuciennik, E., Kciuk, M., & Śliwińska, A. (2025). Overview of Metformin and Neurodegeneration: A Comprehensive Review. Pharmaceuticals, 18(4), 486. https://doi.org/10.3390/ph18040486
Vancouver
Kruczkowska W, Gałęziewska J, Buczek P, Płuciennik E, Kciuk M, Śliwińska A. Overview of Metformin and Neurodegeneration: A Comprehensive Review. Pharmaceuticals. 2025;18(4):486. doi:10.3390/ph18040486
BibTeX
@article{Kruczkowska2025,
author = {Kruczkowska, Weronika and Gałęziewska, Julia and Buczek, Paulina and Płuciennik, Elżbieta and Kciuk, Mateusz and Śliwińska, Agnieszka},
title = {Overview of Metformin and Neurodegeneration: A Comprehensive Review},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {4},
pages = {486},
doi = {10.3390/ph18040486}
}
EUVIMED